Autor segons l'article: Kaźmierczak-Siedlecka K; Skonieczna-żydecka K; Biliński J; Roviello G; Iannone LF; Atzeni A; Sobocki BK; Połom K
Departament: Bioquímica i Biotecnologia
Autor/s de la URV: Atzeni, Alessandro
Paraules clau: bacteremia chemotherapy clostridium-difficile infection colonization cost-effectiveness analysis fecal microbiota transplantation gut microbiota intestinal integrity metabolites pediatric-patients postbiotics prebiotics probiotics recurrent synbiotics Allogenic hematopoietic stem cell transplantation Fecal microbiota transplantation Gut microbiota Intestinal integrity Postbiotics Prebiotics Probiotics Synbiotics Versus-host-disease
Resum: Nowadays, allogenic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy that is mainly recommended for hematologic malignancies. However, complications (such as graft-versus-host disease, mucositis, disease relapse, and infections) associated with the HSCT procedure contribute to the development of gut microbiota imbalance, gut-barrier disruption, and increased intestinal permeability. In the present narrative review, the crosstalk between gut microbiota products and intestinal homeostasis is discussed. Notably, gut-microbiota-related aspects have an impact on patients’ clinical outcomes and overall survival. In accordance with the most recent published data, gut microbiota is crucial for the treatment effectiveness of many diseases, not only gastrointestinal cancers but also hematologic malignancies. Therefore, it is necessary to indicate a therapeutic method allowing to modulate gut microbiota in HSCT recipients. Currently, fecal microbiota transplantation (FMT) is the most innovative method used to alter/restore gut microbiota composition, as well as modulate its activity. Despite the fact that some previous data have shown promising results, the knowledge regarding FMT in HSCT is still strongly limited, except for the treatment of Clostridium difficile infection. Additionally, administration of prebiotics, probiotics, synbiotics, and postbiotics can also modify gut microbiota; however, this strategy should be considered carefully due to the high risk of fungemia/septicemia (especially in case of fungal probiotics)..
Àrees temàtiques: Cancer research Medicina iii Oncology
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: alessandro.atzeni@urv.cat alessandro.atzeni@urv.cat
Identificador de l'autor: 0000-0002-1804-8606 0000-0002-1804-8606
Data d'alta del registre: 2021-10-16
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Referència a l'article segons font original: Cancers. 13 (18):
Referència de l'ítem segons les normes APA: Kaźmierczak-Siedlecka K; Skonieczna-żydecka K; Biliński J; Roviello G; Iannone LF; Atzeni A; Sobocki BK; Połom K (2021). Gut microbiome modulation and faecal microbiota transplantation following allogenic hematopoietic stem cell transplantation. Cancers, 13(18), -. DOI: 10.3390/cancers13184665
URL Document de llicència: http://repositori.urv.cat/ca/proteccio-de-dades/
DOI de l'article: 10.3390/cancers13184665
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2021
Tipus de publicació: Journal Publications
Repositori URV